Watch Video Now Icon WATCH NOW: Clinical experience with ALPROLIX

Many patients with hemophilia B may adjust their management approach over time to fit their needs1,2

Driving icon

Life change

Ongoing prophylaxis may feel 
burdensome during early adulthood 
or other transitional life stages, 
leading to changes in treatment approach1

Tennis ball icon

Changes in activity

Patients who treat on demand may 
recognize the need to transition 
to prophylaxis2

  • Although prophylaxis is ideal for preventing bleeds, including those in the joints, transitioning to a fixed infusion schedule can be challenging for some patients1,2
  • Patients may feel that they don’t bleed often enough to justify a switch to long-term prophylaxis1


of adult patients with severe hemophilia B switch their treatment approach to accommodate changes in their lifestyle3

ALPROLIX® can meet your patients’ needs regardless of how they may shift over time4




  • ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.


  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.


  • The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.


ALPROLIX® is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use
ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

References: 1. Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677-1686. 2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47. 3. Baumann K, Hernandez G, Witkop M, et al. Impact of mild to severe hemophilia on engagement in recreational activities by US men, women, and children with hemophilia B: the bridging hemophilia experiences, results and opportunities into solutions (B-Hero-S) study. Eur J Haematol. 2017;98:25-34. 4. ALPROLIX [package insert]. Waltham, MA: Bioverativ Therapeutics Inc.